Pipeline
BioMimetix is a clinical stage company with two novel drugs being developed in Phase 1 and Phase 2 trials.
BMX-001 is a sub-cutaneous injection for oncologic conditions.
BMX-010 is a topical for dermatologic conditions.
Program:
BMX-001
Therapeutic Indication
High-Grade Glioma
Orphan Designation
Fast-Track
- Phase 1 100%
- Phase 2 100%
Therapeutic Indication
Head and Neck Cancer
- Phase 1/2 100%
- Phase 2 0%
Therapeutic Indication
Multiple Brain Mets
- Phase 2 50%
Therapeutic Indication
Anal Cancer
- Phase 1 50%
Therapeutic Indication
Rectal Cancer
- Phase 2 0%
Program:
BMX-010
Therapeutic Indication
Atopic Dermatitis
- Phase 1 100%
- Phase 2 50%
Therapeutic Indication
Pruritus (itch)
- Phase 1 100%
- Phase 2 50%
Therapeutic Indication
Psoriasis
- Phase 1 100%
Therapeutic Indication
Rosacea
- Phase 2 50%
- Phase 2 50%